Zobrazeno 1 - 10
of 55
pro vyhledávání: '"Anjuli Nayak"'
Publikováno v:
Clinical Therapeutics. 31:99-107
Background: Seasonal allergic rhinitis (SAR) is an allergen-induced inflammatory reaction that occurs during periods of high pollen count. Current treatments for SAR include allergen avoidance, systemic antihistamines, and steroidal and nonsteroidal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64afbd6f5a85f0569c28bf08bda94129
https://doi.org/10.1016/j.clinthera.2009.01.016
https://doi.org/10.1016/j.clinthera.2009.01.016
Autor:
Michael J Maloney, Javier T Quesada, Robert E Grubbe, Nathan Segall, Barbara Kittner, Arden L Levy, Anjuli Nayak
Publikováno v:
Allergy and Asthma Proceedings. 29:380-385
Allergic rhinitis (AR) is a common chronic condition in children and may impact a child's quality of life. Increasing treatment compliance may improve quality of life. An oral suspension of fexofenadine hydrochloride (HCl) has been developed to ease
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8b3c7521c4a7390abd8d31927a815fef
https://doi.org/10.2500/aap.2008.29.3136
https://doi.org/10.2500/aap.2008.29.3136
Autor:
Patrick Darken, Bobby Q. Lanier, Harold B. Kaiser, Anjuli Nayak, Craig LaForce, Nancy Hall, Mark A. Wingertzahn, William E. Berger
Publikováno v:
Pediatric Asthma, Allergy & Immunology. 21:73-82
Two double-blind studies in children aged 6 to 11 years with allergic rhinitis (AR) assessed the efficacy and safety of the intranasal corticosteroid ciclesonide. In the first study, 618 patients w...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::34f20b58fdf0bd0f228abce1e15f096e
https://doi.org/10.1089/pai.2007.0022.73
https://doi.org/10.1089/pai.2007.0022.73
Autor:
Jerry Herron, Mark A. Wingertzahn, Paul H. Ratner, Nancy Hall, Michael Weiswasser, Ruediger Nave, Kenneth Kim, Anjuli Nayak
Publikováno v:
Pediatric Asthma, Allergy & Immunology. 20:229-242
Two double-blind studies in children aged 2 to 5 years with perennial allergic rhinitis (PAR) assessed the safety and efficacy of the intranasal corticosteroid ciclesonide. In the first study, 133 patients were randomized to once-daily ciclesonide 25
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a6d6a9e825b6c989ad29ce0e05bb91a1
https://doi.org/10.1089/pai.2007.002
https://doi.org/10.1089/pai.2007.002
Autor:
Ronald B. Langdon, Anjuli Nayak
Publikováno v:
Drugs. 67:887-901
Cysteinyl-leukotrienes (CysLTs) are endogenous mediators of inflammation and play an important role in allergic airway disease by stimulating bronchoconstriction, mucus production, mucosal oedema and inflammation, airway infiltration by eosinophils,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::308aacac19556c3daff6bd579069cf43
https://doi.org/10.2165/00003495-200767060-00005
https://doi.org/10.2165/00003495-200767060-00005
Autor:
Jonathan Corren, Anjuli Nayak, Jonathan A. Bernstein, William E. Berger, H. Sacks, William W. Storms
Publikováno v:
Clinical Therapeutics. 27:543-553
Azelastine nasal spray and oral cetirizine are selective histamine H(1)-receptor antagonists that are approved in the United States for the treatment of seasonal allergic rhinitis (SAR).The objective of the present study was to compare the efficacy a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d43422aa35833d6789145a57b44f380
https://doi.org/10.1016/j.clinthera.2005.04.012
https://doi.org/10.1016/j.clinthera.2005.04.012
Publikováno v:
Chest. 122:1956-1965
Background Beclomethasone dipropionate (BDP) has been formulated as an extrafine aerosol (hydrofluoroalkane-134a [HFA]-BDP) [QVAR; 3M Pharmaceuticals; St Paul, MN], which gives improved lung deposition compared with chlorofluorocarbon (CFC)-BDP. The
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::87a37207d66b5717f7e46a1c80d07677
https://doi.org/10.1378/chest.122.6.1956
https://doi.org/10.1378/chest.122.6.1956
Autor:
Richard R. Lorber, William W. Busse, Ger Rikken, Andrew Pedinoff, Melvyn R. Danzig, Guy A. Settipane, B.Lauren Charous, Eli O. Meltzer, S. James Zinreich, Anjuli Nayak
Publikováno v:
Annals of Allergy, Asthma & Immunology. 89:271-278
Background Mometasone furoate nasal spray (MFNS) 400 μg, twice daily, as adjunctive treatment with oral antibiotic significantly improved symptoms of recurrent rhinosinusitis. Objective To evaluate the effectiveness and safety of MFNS 200 μg, twice
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17e9d9c48e519491142712d0f37e864f
https://doi.org/10.1016/s1081-1206(10)61954-0
https://doi.org/10.1016/s1081-1206(10)61954-0
Mometasone furoate: efficacy and safety in moderate asthma compared with beclomethasone dipropionate
Autor:
Mark L. Vanderwalker, Keith B Nolop, Anjuli Nayak, David F. Graft, Judy E. Harrison, Frank J. Picone, Robert A. Nathan, Tahir Ahmed, James D. Wolfe, Michael S. Lawrence
Publikováno v:
Annals of Allergy, Asthma & Immunology. 86:203-210
Mometasone furoate (MF) is a new inhaled glucocorticoid administered by dry powder inhaler (DPI).MF-DPI was evaluated for safety and efficacy and compared with placebo DPI and beclomethasone dipropionate (BDP) administered by metered dose inhaler (MD
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3fb379d0d2e428a0a4892d0b0b6f1c69
https://doi.org/10.1016/s1081-1206(10)62692-0
https://doi.org/10.1016/s1081-1206(10)62692-0
Publikováno v:
Clinical Drug Investigation. 21:25-32
To evaluate the efficacy and tolerability of desloratadine 5mg once daily, a new, selective, H1-receptor antagonist, for the treatment of patients with seasonal allergic rhinitis (SAR) during the two major pollen seasons in the USA. Two multicentre,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::abc43d903919d91e501cfddf3972c573
https://doi.org/10.2165/00044011-200121010-00004
https://doi.org/10.2165/00044011-200121010-00004